PSI Advisors’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

PSI Advisors’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-700	Closed	-$7K	–	653
2019 Q4	$7K	Buy	+700	New	+$7.04K	﹤0.01%	512

Other funds holding CYAD

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

PSI Advisors's CYAD Position: Q1 2020 in Review

PSI Advisors sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q1 2020, closing a stake of 700 shares — an estimated $7K sold.

PSI Advisors first reported a position in CYAD in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 8 funds tracked by Wall St. Rank hold CYAD as of Q1 2020.

PSI Advisors reported no remaining Celyad Oncology SA American Depositary Shares position as of Q1 2020 after selling out during the quarter.
PSI Advisors sold 700 Celyad Oncology SA American Depositary Shares shares in Q1 2020, an estimated $7K.
PSI Advisors first reported a position in Celyad Oncology SA American Depositary Shares in Q4 2019 and held it in 1 quarter.
PSI Advisors's Celyad Oncology SA American Depositary Shares position peaked at $7K in Q4 2019.
8 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q1 2020.

Based on PSI Advisors's 13F filing for Q1 2020, filed 15 May 2020.